The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
The three developmental phases in the acceptance and use of depot neuroleptics are described. The practical advantages of these drugs are considered, as well as the extrapyramidal side effects that may result from oral or depot administration. Local (injection site) and other side effects of depot neuroleptics are discussed. Typical plasma drug concentration curves and receptor responses of depot neuroleptics are illustrated. Alternative use of oral drugs and strategies to increase the effectiveness of depot forms are presented. The depot neuroleptics used in Scandinavia today are discussed, and predictions are made regarding their use in the future.
D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001682:Biological Availability; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D004363:Drug Utilization; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D010349:Patient Compliance; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012306:Risk; D012537:Scandinavian and Nordic Countries; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; C011825:fluphenazine depot; D005476:Fluphenazine